The Relationship Between Plasma Cytokine Levels and Response to Selective 
Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with 
Depression and/or Anxiety Disorders

Amitai, Maya; Taler, Michal; Carmel, Miri; Michaelovsky, Elena; Eilat, Tamar; Yablonski, Maya; Orpaz, Naama; Chen, Alon; Apter, Alan; Weizman, Abraham; Fennig, Silvana

doi:10.1089/cap.2015.0147

Datensatz

DATENSATZ AKTIONENEXPORT

Zur Ablage hinzufügen

Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben

Zeitschriftenartikel

The Relationship Between Plasma Cytokine Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with Depression and/or Anxiety Disorders

MPG-Autoren

/persons/resource/persons129892

Chen, Alon
external;
Dept. Stress Neurobiology and Neurogenetics, Max Planck Institute of Psychiatry, Max Planck Society;

Externe Ressourcen

Es sind keine externen Ressourcen hinterlegt

Volltexte (beschränkter Zugriff)

Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.

Volltexte (frei zugänglich)

Es sind keine frei zugänglichen Volltexte in PuRe verfügbar

Ergänzendes Material (frei zugänglich)

Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar

Zitation

Amitai, M., Taler, M., Carmel, M., Michaelovsky, E., Eilat, T., Yablonski, M., et al. (2016). The Relationship Between Plasma Cytokine Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with Depression and/or Anxiety Disorders. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 26(8), 727-732. doi:10.1089/cap.2015.0147.

Zitierlink: https://hdl.handle.net/11858/00-001M-0000-002C-4ABF-A

Zusammenfassung

Objective: In adults there is growing evidence that antidepressant (AD) treatment results in a decline in inflammatory cytokines. This is the first report, to our knowledge, of the relationship between response to selective serotonin reuptake inhibitor (SSRI) treatment for anxiety and/or depression and cytokine levels in children and adolescents. Methods: Forty-one patients who met Diagnostic and Statistical Manual for Mental Disorders, 4th ed. (DSM-IV) criteria for major depressive disorder (MDD) or anxiety disorders participated in study. Their ages ranged from 9 to 18 (14.122.30) years. The patients were treated with fluoxetine for 8 weeks. Plasma concentrations of tumor necrosis factor (TNF)-, interleukin (IL)-6, and IL-1 were measured by enzyme linked immunosorbent assays (ELISA) before and after fluoxetine treatment. Clinical response was measured with several scales, including the Children's Depression Rating Scale-Revised (CDRS-R), the Beck Depression Inventory (BDI), and the Screen for Child Anxiety Related Emotional Disorders (SCARED) Results: The overall response rate was 56%. Antidepressant treatment significantly reduced TNF- levels (p=0.037), with no significant changes in the levels of IL-6 and IL-1. All three proinflammatory cytokines were significantly (p<0.05) higher in SSRI-refractory than in SSRI-responsive patients. Conclusions: Higher levels of TNF-, IL-6, and IL-1 might predict nonresponse to fluoxetine treatment in children.